Biologics, Inc., an integrated oncology services company, is pleased to announce that it has been selected by ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) to be the sole specialty pharmacy provider of Iclusig
(ponatinib) and manager of its Patient Access and Support Services (ARIAD PASS
) program. Iclusig is a treatment for adult patients with refractory chronic myeloid leukemia or Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia.
The decision by ARIAD to utilize a closed distribution network with Biologics was made to ensure a high-touch care model for patients on Iclusig and to increase efficiencies as the product is made commercially available in the U.S. this month.
“We believe Biologics’ approach to patient care and expertise within oncology will deliver the best value and experience to our patients and providers,” said Marty J. Duvall, executive vice president and chief commercial officer at ARIAD. “Our primary objective is to make sure that our patients can access, afford and adhere to this important cancer medicine.”
In addition to providing pharmacy services and supporting the ARIAD PASS program, Biologics will help transition patients from the Iclusig single-patient Investigational New Drug (sIND) program to commercial or patient assistance product offerings. Biologics will also manage ARIAD’s patient assistance and co-pay support programs by conducting benefits investigations and prior authorizations to assess and assist with patient eligibility.
“We’re thrilled to be selected by ARIAD as the exclusive integrated channel partner for Iclusig,” said Dan Duffy, chief business development officer at Biologics. “We share the same goal of making sure patients receive the best care on Iclusig and are dedicated to providing seamless execution.”
Iclusig will be available commercially in the U.S. this month. For more information on Iclusig, please visit
. For more information on the ARIAD PASS program, patients and physicians should call the U.S. toll-free phone number 1-855-447-PASS (7277).
Iclusig is a kinase inhibitor. The primary target for Iclusig is BCR-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL). Iclusig was designed using ARIAD’s computational and structure-based drug design platform specifically to inhibit the activity of BCR-ABL. Iclusig targets not only native BCR-ABL but also its isoforms that carry mutations that confer resistance to treatment, including the T315I mutation, a mutation which has been associated with resistance to other approved TKIs.